The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics, Inc. announced that CEO Paul Peter Tak is presenting at the Stifel 2026 Virtual Targeted Oncology Forum.
The company is sharing new updates on its clinical pipeline with a particular focus on prostate cancer, non-small cell lung cancer (NSCLC), and recurrent glioma. This event provides investors and healthcare professionals an early look at Candel Therapeutics, Inc.'s current strategy and research progress as it works to advance therapies in the oncology sector.
Candel CEO Paul Peter Tak has previously called for stronger patient engagement to accelerate drug discovery at BioEquityEurope. The company’s leadership has also received recognition for regulatory excellence, as Chief Regulatory Officer Susan Stewart was named among RAPSorg 50 for 50. These developments reflect Candel Therapeutics’ focus on both patient-driven innovation and regulatory standards.